March 27 (Reuters) - The United States Food and Drug Administration rejected Adamis Pharmaceuticals Corp's injection for treating severe allergic reactions, the company said on Friday.

The pre-filled epinephrine injection, is being developed to treat acute anaphylaxis, a severe allergic reaction that can cause death.

Adamis said the questions raised by the FDA largely pertained to the volume of the dose delivered by the pre-filled injection.

The company said it would meet with the FDA to discuss the future of the product.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das)